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Summary This study examined the efﬁcacy and safety of zonisamide as monother-
apy in pediatric patients with epilepsy. Seventy-seven children with epilepsy (ages
8 months–15 years) were treated with zonisamide. Nine patients were withdrawn
early because of side effects; these patients were included in side effect but not
efﬁcacy analyses. Zonisamide dosages were initiated at approximately 2mg/kg per
day and adjusted for each patient individually to a maximum of 12mg/kg per day.
Among 44 patients with cryptogenic/symptomatic partial epilepsy, 36 (82%) be-
came seizure free; 4 (9%) had a ≥50% reduction in seizure frequency; and 4 (9%)
had no change in seizures with zonisamide treatment. Of 11 patients with crypto-
genic/symptomatic generalized epilepsy, 10 (91%) became seizure free, and 1 ex-
perienced no change with zonisamide treatment. Similarly, 4 patients (100%) with
idiopathic partial epilepsy, and 8 of 9 patients (89%) with idiopathic generalized
epilepsy became seizure free with zonisamide treatment; in the last group, 1 ex-
perienced no change. Thirty patients (39%) reported side effects, including som-
nolence (11.7%), decreased spontaneity (7.8%), anorexia (6.5%), and rash (6.5%).
Thus, zonisamide is effective for partial seizures with or without secondarily gen-
eralized seizures in children and should be considered a broad-spectrum antiepilepsy
agent.
© 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.
Introduction
Whenever possible, monotherapy should be a goal
for patients with epilepsy. This study examines the
safety and efﬁcacy of zonisamide as monotherapy
in pediatric patients with epilepsy.
*Corresponding author. Tel.: +81 3 3833 8381;
fax: +81 2 3831 9488.
Methods
Patients
The study group consisted of 77 children with
epilepsy (ages 8 months—15 years) who were pa-
tients from the Department of Pediatrics, Keio
University Hospital, and the pediatric departments
of Keio University-afﬁliated hospitals. These pa-
tients were observed for sufﬁcient periods to de-
termine their baseline values of frequency and
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severity of seizures before zonisamide treatment.
Nine patients dropped out at an early stage of zon-
isamide administration because of somnolence and
anorexia. These 9 patients were excluded from the
efﬁcacy analysis, but were included in the study
of adverse effects. Excluding these 9 patients, the
study group comprised 68 patients. Fifty had never
taken antiepilepsy drugs (AEDs); the remaining 18
were nonresponders to AEDs. In these 18 patients,
the previous AEDs were gradually decreased and
discontinued during zonisamide administration.
The method for gradual decrease and discontinu-
ation was not ﬁxed, but was left up to individual
physicians. As this study was conducted before
the market introduction of zonisamide, patients’
parents provided verbal informed consent before
zonisamide treatment began.
Study design
Zonisamide administration was initiated using a
standard procedure for pediatric zonisamide ad-
ministration in Japan. That is, approximately
2mg/kg per day of zonisamide was administered in
2 equally-divided doses in the morning and evening.
When no change, or only a partial decrease in
seizures was noted following an initial dose, the
dosage was then increased by 1–2mg/kg per day
every 1–2 weeks. Provided no unacceptable adverse
effects occurred, zonisamide could be increased to
up to a dose of 12mg/kg per day as necessary to
decrease seizures.
Efﬁcacy against seizures, adverse effects, and
serum concentration was evaluated. Zonisamide
concentrations were determined using blood sam-
ples taken 2—4h after morning administration, at
2 weeks or more following a change in dosage.
Evaluation of efﬁcacy
In general, reductions in both seizure frequency
and seizure severity are important criteria for ef-
ﬁcacy, but because evaluation of seizure severity
would have depended on a physician’s subjective
judgment, we evaluated only seizure frequency as
follows:
• ‘‘Excellent response’’—Patients with ≥1 seizure/
month before study entry who became seizure
free for ≥3 months after zonisamide adminis-
tration. Also included were patients with <1
seizure/month before zonisamide who became
seizure free for a period of at least 3 times longer
than the maximal seizure-free period before
zonisamide treatment.
• ‘‘Good response’’—Patients who experienced a
≥50% reduction in seizures.
• ‘‘Poor response’’ or ‘‘no response’’—Patients
who experienced a <50% reduction in seizures,
or no effect, respectively.
Evaluation of safety
Adverse effects were investigated by means of
interviews, clinical assessments, and blood tests
(complete blood count, glutamic oxaloacetic
transaminase, glutamic pyruvate transaminase,
gamma glutamyl traspeptidase, blood urea ni-
trogen, creatinine, calcium, potassium, alkaline
phosphatase, protein analysis, immunoglobulin,
antinuclear antibody, and urinalysis), using samples
collected monthly throughout the study.
Patient clinical proﬁles
Table 1 shows the 68 patients in the study group
classiﬁed according to the 1989 International
League Against Epilepsy classiﬁcation. Forty-eight
patients had localization-related epilepsies; 44 had
symptomatic/cryptogenic epilepsy; and 4 had idio-
pathic epilepsy. These 4 patients had benign child-
hood epilepsy with centrotemporal spikes (Rolandic
epilepsy). Twenty patients had generalized epilep-
sies; of these, 11 had symptomatic/cryptogenic
epilepsy, and 9 had idiopathic epilepsy. Patients
with West syndrome, Lennox-Gastaut syndrome,
childhood absence epilepsy, and severe myoclonic
epilepsy in infancy were excluded because of eth-
ical problems probably due to poor efﬁcacy of
zonisamide in Japan trials.1,2
Patients’ ages at the time of zonisamide adminis-
tration ranged from 8 months to 15 years, 8 months
(mean = 8 years, 3 months). Zonisamide adminis-
tration periods ranged from 6 months to 5 years, 8
months (mean = 1 year, 9 months) among respon-
ders (patients with ‘‘excellent’’ and ‘‘good’’ re-
sponses) and from 3 to 5 months (mean= 4 months)
Table 1 Clinical proﬁles of 68 patients.
Type of epileptic syndromea Number of patients
Localization-related 48
Symptomatic/cryptogenic 44
Idiopathic 4
Generalized 20
Symptomatic/cryptogenic 11
Idiopathic 9
a Data were analyzed using the International League
Against Epilepsy classiﬁcation (1989).
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Table 2 Clinical trials of zonisamide monotherapy in children: efﬁcacy by epileptic syndrome.
Syndrome type Response to zonisamide
Excellent Good Poor or none
Localization-related
Symptomatic/cryptogenic (n = 44) 36 (82%) 4 (9%) 4 (9%)
Idiopathic (n = 4)a 4 (100%)
Generalized
Symptomatic/cryptogenic (n = 11)b 10 (91%) 1 (9%)
Idiopathic (n = 9)c 8 (89%) 1 (11%)
a Benign childhood epilepsy with centrotemporal spike.
b West syndrome and Lennox-Gastaut syndrome were not included.
c Childhood absence epilepsy was not included.
among nonresponders (patients with ‘‘poor’’ or ‘‘no
responses’’).
Results
Efﬁcacy
The efﬁcacy of zonisamide treatment by epileptic
syndrome is shown in Table 2. In localization-related
epilepsy, efﬁcacy was ‘‘excellent’’ in 36 of 44
symptomatic/cryptogenic patients (82%); ‘‘good’’
in 4 patients (9%); and ‘‘poor’’ or ‘‘ineffective’’
in 4 patients (9%). Efﬁcacy was ‘‘excellent’’ in
Table 3 Clinical trials of zonisamide monotherapy in children: efﬁcacy by syndrome and seizure type.
Syndrome/seizure type Response to zonisamide
Excellent Good Poor or none
Localization-related
Symptomatic/cryptogenic
Simple partial seizures (n = 9) 8 (89%) 1 (11%)
Complex partial seizures (n = 29) 23 (79%) 2 (7%) 4 (14%)
Partial seizure secondarily
generalized tonic—clonic
seizures (n = 28)
23 (82%) 3 (11%) 2 (7%)
Idiopathic
Simple partial seizures 4 (100%)
Generalized
Symptomatic/cryptogenic
Tonic—clonic seizures (n = 3) 3 (100%)
Clonic seizures (n = 4) 4 (100%)
Atonic seizures (n = 5) 4 (80%) 1 (20%)
Myoclonic seizures (n = 2) 1 (50%) 1 (50%)
Atypical absence seizures (n = 2) 1 (50%) 1 (50%)
Idiopathic
Tonic—clonic seizures (n = 9) 8 (89%) 1 (11%)
all 4 idiopathic epilepsy patients. In generalized
epilepsy, efﬁcacy was ‘‘excellent’’ in 10 of 11
symptomatic/cryptogenic epilepsy patients (91%)
and ‘‘excellent’’ in 8 of 9 idiopathic epilepsy pa-
tients (89%).
Table 3 shows efﬁcacy against seizure by epilep-
tic syndrome and seizure type. Seizure type was
diagnosed by seizure history and interictal EEG
primarily, with ictal EEG used in only a few cases;
video EEG was not used. In localization-related
epilepsy patients, efﬁcacy was ‘‘excellent’’ in
symptomatic/cryptogenic epilepsy patients with
simple partial seizures (89%), complex partial
seizures (79%), and secondarily generalized tonic—
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Figure 1 Ictal EEG. Ictal activity was recorded as rhythmic slow wave (3—3.5Hz) over the right hemisphere (fronto-
central dominant). The patient was diagnosed with symptomatic localization-related seizures with tuberous sclerosis.
clonic seizures (82%). Combining these patients and
‘‘good’’ response patients, responders accounted
for approximately 90%.
In patients with symptomatic/cryptogenic gen-
eralized epilepsy, groups for each seizure type
included only a small number of patients, but ef-
ﬁcacy was seen against tonic—clonic, clonic, and
atonic seizures (Table 3). Because atonic seizures
were not evaluated by video-EEG, inclusion of
tonic or myoclonic elements is unknown. Of the 9
patients with idiopathic epilepsy, all patients had
tonic—clonic seizures, and among these, 8 (89%)
were ‘‘excellent’’ responders.
Fig. 1 shows an ictal EEG recording of a patient
with symptomatic localization-related epilepsy as-
Figure 2 Zonisamide serum concentration and efﬁcacy. Open circles indicate an ‘‘excellent’’ response, open triangle,
a ‘‘good’’ response, and ×’s are a ‘‘poor’’ or ‘‘no response.’’ Solid triangles indicate a ‘‘good’’ response, but
discontinuation because of adverse effects.
sociated with tuberous sclerosis. The patient was
25 years old and an EEG had been recorded 11 years
earlier. The EEG showed the immediate appearance
of rhythmic slow wave at 3—3.5Hz after the on-
set of a seizure, mainly in frontocentral cortex of
the right hemisphere. There was no epileptic dis-
charge during interictal period. Despite receiving
nitrazepam and phenobarbital, the patient had ex-
perienced about 10 seizures a day at age 14. Zon-
isamide had initially been used as adjunctive ther-
apy. Seizures had disappeared 11 days after start-
ing zonisamide treatment. The doses of nitrazepam
and phenobarbital were gradually reduced, and ﬁ-
nally the patient had been treated with zonisamide
as monotherapy (300 and 400mg/day; dose was in-
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creased because of body weight gain; plasma zon-
isamide concentration was 20 and 20.3g/mL, re-
spectively.) As of his last visit, he had been free
from seizures for 11 years.
Fig. 2 shows the relationship between efﬁcacy
and serum concentration of zonisamide. There
was no apparent relationship between efﬁcacy and
serum zonisamide concentration in any seizure
types. As shown in Fig. 2, only 2 patients (closed
triangle) discontinued zonisamide treatment. They
were rapidly titrated with zonisamide (2mg/kg per
day a week or more) because of frequent seizures,
and zonisamide concentrations in their serum ex-
ceeded 40g/mL. They were discontinued from
zonisamide treatment because of adverse events,
and unsatisfactory reduction of seizures.
Safety
Side effects were reported for 30 patients (39%).
Table 4 presents data on adverse effects of zon-
isamide, with data from the present study con-
trasted with data from combined multicenter clin-
ical studies of 1008 adult and pediatric patients
in Japan (which includes adverse effects both in
zonisamide add-on and zonisamide monotherapy).2
Adverse events were observed in 30 out of 77
patients (39%) in our study. By comparison, in com-
bined multicenter studies in Japan2, adverse events
were observed in 517 out of 1008 patients (51.3%),
but in only 16 out of the 55 patients receiving zon-
isamide monotherapy (29%). As shown in Table 4,
adverse effects characteristic of zonisamide in-
clude impairment of higher mental function and
gastrointestinal disorders. However, evaluation of
the former is subjective and qualitative, and there
is a need for additional objective, quantitative
evaluation. The incidence of subjective hypohidro-
sis was low in the multicenter trials at 1 in 1008
Table 4 Adverse effects of zonisamide used as adjunctive therapy or monotherapy in adults and children.
Adverse effects Monotherapy in
children
(n = 77); our data
Open-label multicenter studies in
adults and children (n = 1008)2
Total of add-on and monotherapy Monotherapy (n = 55)
Total 30 (39.0%) 517 (51.3%) 16 (29.1%)
Drowsiness 9 (11.7%) 245 (24.3%) 5 (9.1%)
Decrease of spontaneity 6 (7.8%) 55 (5.5%) 3 (5.5%)
Irritability 5 (6.5%) 35 (3.5%) 0
Loss of appetite 5 (6.5%) 111 (11%) 4 (7.3%)
Skin rash 5 (6.5%) 24 (2.4%) 3 (5.5%)
Decrease of sweat 2 (2.6%) 1 (0.1%) 0
Positive ANA 2 (2.6%) 0 0
Low IgA 1 (1.3%) 0 0
(0.1%)2; in our study 2 of 77 (2.6%, subjective eval-
uation) experienced hypohidrosis that disappeared
at the end of summer.
Fig. 3 shows serum zonisamide concentrations
obtained immediately after manifestation of ad-
verse effects following zonisamide administration.
Patients whose adverse events were transient and
disappeared included 2 patients in whom zon-
isamide dosage was decreased temporarily, and
patients in whom dosage was continued without
change. There was no clear relationship between
occurrence of adverse events and serum zonisamide
concentrations as shown in Fig. 3.
A decreased serum IgA level (14mg/dL) without
a propensity to infection was found in a 5-year-old
girl with zonisamide monotherapy about 4 months
after the initiation of treatment. Her serum IgA con-
centration was 132mg/dL before zonisamide treat-
ment. Although zonisamide treatment was contin-
ued thereafter, the serum IgA level in the patient
remained unchanged.
Discussion and conclusions
Table 5 shows the efﬁcacy of zonisamide in pedi-
atric patients: in the left column, results of a mul-
ticenter study of children by Oguni et al.1; in the
center column, our study results; and, in the right
column, results from the multicenter trials.2 In the
3 data sets, the efﬁcacy of zonisamide was evalu-
ated by seizure types, not by epileptic syndromes.
For partial seizures, zonisamide appears to show
high efﬁcacy, especially in the pediatric studies, but
this efﬁcacy is also attributable to the large num-
ber of patients who had received no previous treat-
ment (i.e., newly-diagnosed patients). One other
important point is the inclusion of cases in which
zonisamide as add-on therapy suppressed seizures
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Figure 3 Zonisamide serum concentration and safety. Open circles indicate adverse events that were transient and
disappeared. Solid circles represent patients whose treatment was discontinued. Open triangles represent patients
in whom zonisamide was continued without change.
Table 5 Open-label trials of zonisamide in Japan.
Seizure type Multicenter trials in
children, including
polytherapy1
Our data of monotherapy
in children
Multicenter trials of
monotherapy in adults
and children2
Partial
SPS 14/30 (47%) 13/13 (100%) 12/14 (86%)
CPS 33/111 (30%) 25/29 (86%) 21/26 (81%)
pGTC 10/34 (29%) 26/28 (93%) 12/18 (67%)
Generalized
TC 5/19 (26%) 15/16 (94%) 5/9 (56%)
Tonic 6/48 (12%) — 2/7 (29%)
Myoclonic 1/5 (20%) 1/2 (50%) —
Absence 2/5 (40%) — —
Number of responders (≥50% reduced in seizures)/number of patients; SPS: simple partial seizures; CPS: complex
partial seizures; pGTC: partial onset generalized tonic—clonic seizures; TC: tonic—clonic seizures.
and transition to zonisamide monotherapy was suc-
cessful. Zonisamide also appears to be effective
as monotherapy of generalized seizures; the small
number of cases indicates a need for further study.
Data for the incidence of hypohidrosis from this
study was compared with that of previous reports in
Table 6 Hypohidrosis associated with zonisamide in Japan.
Reference Number of patients with hypohidrosis/total number of patients
Open-label multicenter trials2 1/1008 (0.1%, polytherapy, children)
Seki et al. (children) 2/77 (2.6%, monotherapy)
Okumura et al.a (children)3 12/70 (17%, monotherapy 4, polytherapy 8)
Ohtani et al. (children)4 4/58 (7%)
Fujita et al. (children)5 4 (total unknown)
Hosoda et al. (children)6 38/153 (24.8%)
a Decreased sweat responses were evaluated by heat loading and acetylcholine loading tests.
Japan (Table 6). In the premarketing stage, the in-
cidence was 1 in 1008 patients (0.1%) and barely re-
ceived attention. After market introduction, cases
reported among children subsequently increased.
Many of the cases were observed in the hot period
of summer. Okumura et al.3 have hypothesized that
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zonisamide may suppress the perspiration function
of sweat glands, but further study is needed. In
many cases, hyperthermia provided an opportunity
to reveal hypohidrosis. Because the condition is of-
ten transient, there is no need to discontinue zon-
isamide for this reason alone except in special cir-
cumstances, and symptomatic treatment is accept-
able. However, if zonisamide is used in tropical or
subtropical regions, the potential for greater prob-
lems exists.
In interpreting these data, it is important to note
characteristics of patient samples differ in quality
and quantity in the pre- and postmarketing stud-
ies of new AEDs, including zonisamide. Premarket-
ing studies proceed with a patient group presumed
to be somewhat homogeneous. In postmarketing
phases, patient groups tend to be more heteroge-
neous. There are also fewer patients in premarket-
ing phases than in postmarketing phases. In addi-
tion, the physicians managing AEDs during premar-
keting studies are virtually all specialists; this is not
true in postmarketing studies.
In the postmarketing reappraisal of the efﬁ-
cacy and safety of zonisamide determined during
premarketing phases, certain phenomena should
be considered. Frequent clinical experience with
postmarketing use of new AEDs includes; (1) a pat-
tern of use for many epileptic syndromes, (2) an
unanticipated expansion of the efﬁcacy spectrum;
(3) a corresponding appearance of unanticipated
adverse effects; and (4) some change in the status
of adverse effects deemed extremely rare during
premarketing trials.
Finally, there are 2 important points to be made
about the advantageous use of zonisamide regard-
ing patient selection and administration protocol.
First, although subsequent experience may change
the current thinking, use of zonisamide should
be precluded in West syndrome, Lennox-Gastaut
syndrome, and SME in infancy because there are
other effective treatments or because of doubts
about zonisamide efﬁcacy. Secondly, to minimize
adverse effects and heighten efﬁcacy, the follow-
ing protocol is recommended: (1) initiate zon-
isamide with 1—2mg/kg per day; (2) for patients
with moderately frequent seizures, increase zon-
isamide gradually on the order of 1mg/kg per
day every 1—2 weeks; and (3) for patients in
whom seizure control is inadequate, increase zon-
isamide gradually to a serum concentration of
40—50g/mL, depending on the patients, with due
attention to mental activity and gastrointestinal
symptoms.
In conclusion, although our current experience of
monotherapy is limited to a small number of pa-
tients, zonisamide may become a ﬁrst-line AED for
both adults and children. However, further evalua-
tion is needed with respect to efﬁcacy, safety, and
applications in generalized epilepsy.
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